Patent · US Active

Soluble Fcγ receptor for treatment of autoimmune bullous diseases

US9981009B2 · kind B2 · utility

1Cited by

2References

10Claims

0Family size

Assignee

SUPPREMOL GMBH · DE

Inventors

Ralf Ludwig · Preußisch Oldendorf, DE
Peter Sondermann · Stockdorf, DE
Dominik Ter Meer · Munich, DE

Key dates

Filing date	Oct 16, 2013
Grant date	May 29, 2018
Priority date	—
Expiry date	Oct 16, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/70535
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention generally relates to the field of biotechnology and medicine. It provides an agent, a pharmaceutical composition and a kit for treatment of autoimmune bullous diseases (AMDB). More specifically, the invention relates to the use of a soluble Fc gamma receptor for treating AMDB, and a pharmaceutical composition and a kit comprising said receptor. It further involves a method of treatment of AMDB.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.